These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 10752651)

  • 1. Adjuvant cyclophosphamide, methotrexate, fluorouracil (CMF) in breast cancer--is it cost-effective?
    Norum J
    Acta Oncol; 2000; 39(1):33-9. PubMed ID: 10752651
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adjuvant fluorouracil, epirubicin and cyclophosphamide in early breast cancer: is it cost-effective?
    Norum J; Holtmon M
    Acta Oncol; 2005; 44(7):735-41. PubMed ID: 16227165
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The cost-effectiveness of adjuvant chemotherapy for early breast cancer: A comparison of no chemotherapy and first, second, and third generation regimens for patients with differing prognoses.
    Campbell HE; Epstein D; Bloomfield D; Griffin S; Manca A; Yarnold J; Bliss J; Johnson L; Earl H; Poole C; Hiller L; Dunn J; Hopwood P; Barrett-Lee P; Ellis P; Cameron D; Harris AL; Gray AM; Sculpher MJ
    Eur J Cancer; 2011 Nov; 47(17):2517-30. PubMed ID: 21741831
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of adjuvant chemotherapy with cyclophosphamide+methotrexate+fluorouracil in patients with node-positive breast cancer.
    Messori A; Becagli P; Trippoli S; Tendi E
    Eur J Clin Pharmacol; 1996; 51(2):111-6. PubMed ID: 8911873
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Docetaxel in combination with doxorubicin and cyclophosphamide as adjuvant treatment for early node-positive breast cancer: a cost-effectiveness and cost-utility analysis.
    Wolowacz SE; Cameron DA; Tate HC; Bagust A
    J Clin Oncol; 2008 Feb; 26(6):925-33. PubMed ID: 18281666
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adjuvant cyclophosphamide, methotrexate and fluorouracil for node-positive breast cancer: a lifetime cost-utility analysis based on a modified Q-TWIST method.
    Trippoli S; Becagli P; Messori A
    Eur J Clin Pharmacol; 1997; 53(3-4):281-2. PubMed ID: 9476047
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost analysis comparing an anthracycline/docetaxel regimen to CMF in patients with early stage breast cancer.
    Braun M; Jacobs VR; Wagenpfeil S; Sattler D; Harbeck N; Nitz U; Bernard R; Kuhn W; Ihbe-Heffinger A
    Onkologie; 2009 Sep; 32(8-9):473-81. PubMed ID: 19736510
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of adjuvant chemotherapy with methotrexate and fluorouracil with and without cyclophosphamide in breast cancer patients with one to three positive axillary lymph nodes.
    Shapiro CL; Gelman RS; Hayes DF; Osteen R; Obando A; Canellos GP; Frei E; Henderson IC
    J Natl Cancer Inst; 1993 May; 85(10):812-7. PubMed ID: 8487326
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness analysis of adjuvant docetaxel, doxorubicin, and cyclophosphamide (TAC) for node-positive breast cancer: modeling the downstream effects.
    Au HJ; Golmohammadi K; Younis T; Verma S; Chia S; Fassbender K; Jacobs P
    Breast Cancer Res Treat; 2009 Apr; 114(3):579-87. PubMed ID: 18443903
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Information technology facilitates cost-effectiveness analysis in developing countries: an observational study of breast cancer chemotherapy in Taiwan.
    Shih YC; Pan IW; Tsai YW
    Pharmacoeconomics; 2009; 27(11):947-61. PubMed ID: 19888794
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Burdens and benefits of adjuvant cyclophosphamide, methotrexate, and fluorouracil and tamoxifen for elderly patients with breast cancer: the International Breast Cancer Study Group Trial VII.
    Crivellari D; Bonetti M; Castiglione-Gertsch M; Gelber RD; Rudenstam CM; Thürlimann B; Price KN; Coates AS; Hürny C; Bernhard J; Lindtner J; Collins J; Senn HJ; Cavalli F; Forbes J; Gudgeon A; Simoncini E; Cortes-Funes H; Veronesi A; Fey M; Goldhirsch A
    J Clin Oncol; 2000 Apr; 18(7):1412-22. PubMed ID: 10735888
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sequential methotrexate and fluorouracil for the treatment of node-negative breast cancer patients with estrogen receptor-negative tumors: eight-year results from National Surgical Adjuvant Breast and Bowel Project (NSABP) B-13 and first report of findings from NSABP B-19 comparing methotrexate and fluorouracil with conventional cyclophosphamide, methotrexate, and fluorouracil.
    Fisher B; Dignam J; Mamounas EP; Costantino JP; Wickerham DL; Redmond C; Wolmark N; Dimitrov NV; Bowman DM; Glass AG; Atkins JN; Abramson N; Sutherland CM; Aron BS; Margolese RG
    J Clin Oncol; 1996 Jul; 14(7):1982-92. PubMed ID: 8683228
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of costs for infusion versus bolus chemotherapy administration: analysis of five standard chemotherapy regimens in three common tumors--Part one. Model projections for cost based on charges.
    Lokich JJ; Moore CL; Anderson NR
    Cancer; 1996 Jul; 78(2):294-9. PubMed ID: 8674006
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Variations in dose and dose intensity of adjuvant CMF chemotherapy for breast cancer throughout the UK.
    Brown RS; Burcombe RJ; Osborne ME; Gaze MN
    Clin Oncol (R Coll Radiol); 2000; 12(5):315-23. PubMed ID: 11315718
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cyclophosphamide, methotrexate and fluorouracil (CMF) versus hormonal ablation with leuprorelin acetate as adjuvant treatment of node-positive, premenopausal breast cancer patients: preliminary results of the TABLE-study (Takeda Adjuvant Breast cancer study with Leuprorelin Acetate).
    Schmid P; Untch M; Wallwiener D; Kossé V; Bondar G; Vassiljev L; Tarutinov V; Kienle E; Lüftner D; Possinger K;
    Anticancer Res; 2002; 22(4):2325-32. PubMed ID: 12174922
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adjuvant chemotherapy in operable breast cancer: cyclophosphamide, methotrexate, and fluorouracil versus chlorambucil, methotrexate, and fluorouracil--11-year results of Swiss Group for Clinical Cancer Research trial SAKK 27/82.
    Senn HJ; Maibach R; Castiglione M; Jungi WF; Cavalli F; Leyvraz S; Obrecht JP; Schildknecht O; Siegenthaler P
    J Clin Oncol; 1997 Jul; 15(7):2502-9. PubMed ID: 9215818
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epirubicin and cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy for early breast cancer.
    Poole CJ; Earl HM; Hiller L; Dunn JA; Bathers S; Grieve RJ; Spooner DA; Agrawal RK; Fernando IN; Brunt AM; O'Reilly SM; Crawford SM; Rea DW; Simmonds P; Mansi JL; Stanley A; Harvey P; McAdam K; Foster L; Leonard RC; Twelves CJ;
    N Engl J Med; 2006 Nov; 355(18):1851-62. PubMed ID: 17079759
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Q-TWiST analysis of cyclophosphamide, epirubicin, fluorouracil versus cyclophosphamide, methotrexate, fluorouracil treatment for premenopausal women with node-positive breast cancer.
    Radice D; Redaelli A
    Pharmacoeconomics; 2005; 23(1):69-75. PubMed ID: 15693729
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase III randomized comparison of postoperative adjuvant chemotherapy with 2-year oral uracil/tegafur versus 6-cycle cyclophosphamide/methotrexate/5-fluorouracil in high-risk node-negative breast cancer patients.
    Watanabe T
    Cancer Chemother Pharmacol; 1998; 42 Suppl():S68-70. PubMed ID: 9750032
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adjuvant CMF for node-negative and estrogen receptor-negative breast cancer patients.
    Zambetti M; Bonadonna G; Valagussa P; Daidone MG; Coradini D; Bignami P; Contesso G; Silvestrini R
    J Natl Cancer Inst Monogr; 1992; (11):77-83. PubMed ID: 1627434
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.